SNYR:NSD-Synergy CHC Corp. Common Stock (USD)

COMMON STOCK | Medical Distribution |

Last Closing

USD 2.49

Change

0.00 (0.00)%

Market Cap

N/A

Volume

0.33M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-20 )

Largest Industry Peers for Medical Distribution

Symbol Name Price(Change) Market Cap
HSIC Henry Schein Inc

N/A

USD 8.13B
PDCO Patterson Companies Inc

N/A

USD 2.74B
AHG Akso Health Group ADR

N/A

USD 0.35B
EDAP EDAP TMS SA

N/A

USD 0.08B
YI 111 Inc

N/A

USD 0.06B
COSM Cosmos Health Inc.

N/A

N/A
ZYXI Zynex Inc

N/A

N/A

ETFs Containing SNYR

MVA:AU VanEck Vectors Australian.. 8.81 % 0.00 %

N/A

USD 0.59B
1555:TSE Nikko Australia REIT 5.09 % 0.00 %

N/A

USD 15.35B
SLF:AU SPDR S&P/ASX 200 Listed P.. 5.03 % 0.00 %

N/A

USD 0.53B
VAP:AU Vanguard Australian Prope.. 4.93 % 0.00 %

N/A

USD 2.97B
DVDY:AU VanEck Morningstar Austra.. 4.51 % 0.00 %

N/A

USD 0.08B
SMLL:AU BetaShares Australian Sma.. 3.15 % 0.00 %

N/A

N/A
VSO:AU Vanguard MSCI Australian .. 1.70 % 0.00 %

N/A

USD 0.95B

Market Performance

  Market Performance vs. Industry/Classification (Medical Distribution) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -43.41% 38% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -43.41% 38% F 18% F
Trailing 12 Months  
Capital Gain 24,800.00% 100% F 100% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 24,800.00% 100% F 100% F
Trailing 5 Years  
Capital Gain 4,050.00% 100% F 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 4,050.00% 100% F 99% N/A
Average Annual (5 Year Horizon)  
Capital Gain 3,791.08% 100% F 99% N/A
Dividend Return 3,791.08% 100% F 99% N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 11,293.35% 13% F 2% F
Risk Adjusted Return 33.57% 88% B+ 67% D+
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector